1. Introduction {#sec1-cancers-11-00601}
===============

Lung cancer accounts for the largest number of cancer-related deaths in the world and its morbidity increases annually \[[@B1-cancers-11-00601]\]. Lung adenocarcinoma (LUAD) is the most common histological subtype of non-small cell lung cancer (NSCLC) and this type of cancer is the leading cause of cancer-related deaths \[[@B2-cancers-11-00601]\]. The survival rate of lung cancer has increased due to effective treatment strategies, including molecularly-targeted drugs and immune checkpoint inhibitors \[[@B3-cancers-11-00601]\]. However, the efficacy of treatments for patients with distant metastases is limited, thereby resulting in poor prognosis \[[@B2-cancers-11-00601]\]. In LUAD, metastasis occurs even if the primary tumor is small \[[@B4-cancers-11-00601],[@B5-cancers-11-00601]\]. Therefore, the prognosis of advanced LUAD patients is poor, with average 5-year survival rates below 20% \[[@B6-cancers-11-00601]\]. Therefore, additional research to identify novel biomarkers for earlier detection and to develop effective targeted molecular therapies for LUAD is indispensable.

A vast number of studies have revealed that an extremely large number of non-coding RNAs are transcribed from the human genome and actually functional in various cellular processes. Among these non-coding RNAs, microRNAs (miRNAs) are endogenous single-stranded RNA molecules (19--22 nucleotides in length) that function as fine-tuners of RNA expression \[[@B7-cancers-11-00601],[@B8-cancers-11-00601],[@B9-cancers-11-00601],[@B10-cancers-11-00601],[@B11-cancers-11-00601]\]. Importantly, a single miRNA can control a large number of RNA transcripts in normal and disease cells \[[@B7-cancers-11-00601],[@B8-cancers-11-00601],[@B9-cancers-11-00601],[@B10-cancers-11-00601],[@B11-cancers-11-00601]\]. Recent studies showed that aberrant expression of miRNAs closely contributes to the pathogenesis of human diseases, including cancers via disruption of RNA networks \[[@B8-cancers-11-00601],[@B9-cancers-11-00601],[@B10-cancers-11-00601],[@B11-cancers-11-00601],[@B12-cancers-11-00601],[@B13-cancers-11-00601]\].

We have been analyzing novel anti-tumor miRNA-mediated oncogenic targets and pathways that contribute to lung tumorigenesis \[[@B14-cancers-11-00601],[@B15-cancers-11-00601],[@B16-cancers-11-00601],[@B17-cancers-11-00601],[@B18-cancers-11-00601],[@B19-cancers-11-00601]\]. Interestingly, our miRNA studies revealed that some passenger strands of miRNAs (e.g., *miR-144-5p* and *miR-145-3p*) derived from miRNA-duplex actually acted as anti-tumor miRNAs in lung squamous cell carcinoma \[[@B15-cancers-11-00601],[@B19-cancers-11-00601]\]. More recently, we demonstrated that two miRNA species derived from *miR-145*-duplex (*miR-145-5p* and *miR-145-3p*) acted as anti-tumor miRNAs in LUAD via targeting several oncogenes \[[@B17-cancers-11-00601]\].

Initially, it was thought that two types of miRNA were derived from double-stranded pre-miRNAs: guide strand miRNAs that control the target genes, and passenger strand miRNAs that lacked function and were degraded \[[@B20-cancers-11-00601]\]. Our studies have altered the conventional understanding of miRNA biogenesis and have shown the importance of exploring passenger strands of miRNAs in cancer cells.

RNA sequencing-based miRNA expression signatures contribute to a new development of molecular pathogenesis of human cancers. miRNA expression signatures in human cancers revealed that two miRNAs derived from *miR-150*-duplex---*miR-150-5p* (the guide strand) and *miR-150-3p* (the passenger strand)---are frequently downregulated in several types of cancers \[[@B21-cancers-11-00601],[@B22-cancers-11-00601],[@B23-cancers-11-00601]\]. Reports of *miR-150-5p* in cancers are scattered across public databases, but there are few reports of *miR-150-3p*. We have analyzed the anti-tumor activity of *miR-150-3p* in esophageal and head and neck squamous cell carcinomas \[[@B22-cancers-11-00601],[@B23-cancers-11-00601]\]. With regard to LUAD, no such reports are available, and this is an important facet of the functional analysis of *miR-150-3p* and the search for target genes.

The aim of this study was to investigate the anti-tumor roles of both strands of *miR-150*-duplex and to identify their targets with close associations with LUAD tumorigenesis. The Cancer Genome Atlas (TCGA) revealed that low expression of *miR-150-5p* and *miR-150-3p* predicted poor prognosis. Ectopic expression of two miRNAs significantly attenuated the malignant phenotypes of cancer cells. Moreover, we identified several oncogenic targets by *miR-150-3p* regulation in LUAD cells.

2. Results {#sec2-cancers-11-00601}
==========

2.1. miR-150-5p and miR-150-3p were Downregulated in Lung Adenocarcinoma (LUAD) Specimens and Cell Lines {#sec2dot1-cancers-11-00601}
--------------------------------------------------------------------------------------------------------

To explore whether *miR-150-5p* and *miR-150-3p* are downregulated in LUAD, expression levels of *miR-150-5p* and *miR-150-3p* in clinical specimens were measured. The characteristics of the patients are recorded in [Table 1](#cancers-11-00601-t001){ref-type="table"}.

We found that expression of the *miR-150* duplex was significantly decreased in LUAD specimens and LUAD cell lines relative to non-cancerous tissues (*p* = 0.0078 and *p* \< 0.0001, respectively, [Figure 1](#cancers-11-00601-f001){ref-type="fig"}A,B). There were positive correlations between the expression levels of *miR-150-5p* and *miR-150-3p* by Spearman's rank test (*r* = 0.7156 and *p* \< 0.0001, [Figure 1](#cancers-11-00601-f001){ref-type="fig"}C). According to the Kaplan--Meier overall survival curves using TCGA database, we found that the low expression levels of *miR-150-5p* and *miR-150-3p* were associated with poor prognosis in LUAD patients (overall survival, *p* = 0.0078 and *p* = 0.0435, respectively, [Figure 1](#cancers-11-00601-f001){ref-type="fig"}D,E).

2.2. Overexpression of miR-150-5p and miR-150-3p Inhibits Cancer Cell Aggressiveness {#sec2dot2-cancers-11-00601}
------------------------------------------------------------------------------------

To investigate the biological functions of *miR-150-5p* and *miR-150-3p* in LUAD, we performed gain-of-function assays using miRNA transfection into LUAD cell lines (A549 and H1299). Cell proliferation assays showed that *miR-150-5p*- and *miR-150-3p*- transfected LUAD cells had reduced cell growth compared with mock- or miR-control-transfected LUAD cells ([Figure 2](#cancers-11-00601-f002){ref-type="fig"}A). Also, cell migratory and invasive abilities were markedly decreased in the LUAD cells transfected with *miR-150-5p* and *miR-150-3p* ([Figure 2](#cancers-11-00601-f002){ref-type="fig"}B,C).

Furthermore, we performed functional analysis by reducing the concentration of *miR-150-3p* (1 nM and 0.1 nM) transfection into LUAD cells. Our data showed that antitumor functions (inhibition of cancer cell proliferation, migration, and invasion) were observed at 1 nM concentration, although there were no antitumor functions at 0.1 nM concentration on A549 and H1299 cells ([Figure S1](#app1-cancers-11-00601){ref-type="app"}).

2.3. Incorporation of miR-150-5p and miR-150-3p into the RNA-induced silencing complex (RISC) in LUAD Cells {#sec2dot3-cancers-11-00601}
-----------------------------------------------------------------------------------------------------------

We next performed immunoprecipitation with antibodies targeting Ago2, which plays a pivotal role in the uptake of miRNAs into the RISC ([Figure S2A](#app1-cancers-11-00601){ref-type="app"}). After transfection of A549 cells with *miR-150-5p* and immunoprecipitation by anti-Ago2 antibodies, *miR-150-5p* levels in the immunoprecipitates were significantly higher than those of mock- or miR-control-transfected cells and those of *miR-150-3p*-transfected cells (*p* \< 0.01; [Figure S2B--D](#app1-cancers-11-00601){ref-type="app"}). Similarly, after *miR-150-3p* transfection (10 nM, 1 nM, and 0.1 nM), substantial amounts of *miR-150-3p* were detected in Ago2 immunoprecipitates (*p* \< 0.01; [Figure S2B--D](#app1-cancers-11-00601){ref-type="app"}).

2.4. Candidate Target Genes of miR-150-5p and miR-150-3p Regulation in LUAD: Clinical Significance of TNS4, SFXN1, SKA3, and SPOCK1 Expression {#sec2dot4-cancers-11-00601}
----------------------------------------------------------------------------------------------------------------------------------------------

Our selection strategy of *miR-150-5p*- and *miR-150-3p*-regulated oncogenic targets is shown in [Figure S3A,B](#app1-cancers-11-00601){ref-type="app"}. A total of 41 and 26 oncogenic targets regulated by *miR-150-5p* and *miR-150-3p* were identified in LUAD cells ([Table 2](#cancers-11-00601-t002){ref-type="table"} and [Table 3](#cancers-11-00601-t003){ref-type="table"}).

In this study, we focused on *miR-150-3p*, which is the passenger strand of the *miR-150* duplex and had pronounced anti-tumor function. We examined the relation between the pathogenesis of LUAD and these targets using TCGA database and found four genes (*TNS4*, *SFXN1*, *SKA3*, *SPOCK1*) that were strongly associated with patient outcomes (5-year overall survival, *p* \< 0.01, [Figure 3](#cancers-11-00601-f003){ref-type="fig"}A--D). Finally, we focused on *TNS4*, the expression of which was strongly associated with poor prognosis of LUAD patients (disease-free survival: *p* = 0.0213 and overall survival: *p* = 0.0003) among the four genes and validated the effect on LUAD cells.

2.5. miR-150-3p Directly Regulated TNS4 in A549 Cells {#sec2dot5-cancers-11-00601}
-----------------------------------------------------

In cells transfected with *miR-150-3p*, the levels of *TNS4* mRNA and TNS4 protein were significantly lower than mock- or miR-control-transfected cells ([Figure 4](#cancers-11-00601-f004){ref-type="fig"}A,B). Furthermore, the expression of *TNS4* mRNA and TNS4 protein was suppressed at the diluted concentration of *miR-150-3p* precursor (1 nM and 0.1 nM) ([Figure S4A,B](#app1-cancers-11-00601){ref-type="app"}).

In order to confirm the binding site of *miR-150-3p*, the nucleotide sequences of 3'UTR (UTR: untranslated region) of *TNS4* in A549 cells was examined independently. Our data showed that several variants of the 3'UTR of *TNS4* existed in A549 cells ([Figure S5](#app1-cancers-11-00601){ref-type="app"}). As a result of sequencing analyses, one putative binding site of the *miR-150-3p* was found in 3'UTR of *TNS4* ([Figure S5](#app1-cancers-11-00601){ref-type="app"}). Based on our sequence data, we used luciferase reporter assays with vectors carrying either the wild-type or deletion-type 3'-UTR of *TNS4* ([Figure 4](#cancers-11-00601-f004){ref-type="fig"}C). We observed significantly reduced luminescence intensities after transfection with *miR-150-3p* and the wild-type 3'-UTR of *TNS4* ([Figure 4](#cancers-11-00601-f004){ref-type="fig"}C). Transfection with the deletion-type vector did not reduced luminescence intensities in A549 cells ([Figure 4](#cancers-11-00601-f004){ref-type="fig"}C). Thus, *miR-150-3p* directly bound to *TNS4* in the 3'-UTR. Although TargetScanHuman database predicted putative binding sites of *miR-150-5p* in 3'UTR of *TNS4*, our sequencing data could not confirm the sequences.

2.6. Expression of TNS4 Protein in Clinical LUAD Specimens {#sec2dot6-cancers-11-00601}
----------------------------------------------------------

Analysis using a tissue microarray was performed to examine TNS4 expression at the protein level. We validated the expression of TNS4 by using immunohistochemical staining. In this study, we stained 20 LUAD specimens and 14 non-cancerous specimens. Clinical information on the tissue microarray is shown in the [Table S2](#app1-cancers-11-00601){ref-type="app"}. Compared with non-cancerous tissues, TNS4 proteins were highly expressed in LUAD specimens ([Figure 5](#cancers-11-00601-f005){ref-type="fig"}).

2.7. TNS4 Silencing Suppresses the Aggressiveness of LUAD Cells {#sec2dot7-cancers-11-00601}
---------------------------------------------------------------

To confirm the effect of *TNS4* on LUAD cells, we used si-*TNS4* to knock down its expression in A549 cells. RT-PCR and Western blotting showed that expression levels of both *TNS4* mRNA and TNS4 protein were markedly reduced by both si-*TNS4*-1 and si-*TNS4*-2 ([Figure 6](#cancers-11-00601-f006){ref-type="fig"}A,B). In functional assays, cell proliferation, migration, and invasive abilities were significantly suppressed by si-*TNS4* transfection in LUAD cells ([Figure 6](#cancers-11-00601-f006){ref-type="fig"}C--E).

2.8. Gain-of-Function Studies by TNS4 Expression Vector {#sec2dot8-cancers-11-00601}
-------------------------------------------------------

To explore whether *TNS4* promoted cell proliferation, migration, and invasive abilities, we transfected pCMV-*TNS4* into H1299 cells and performed functional assays. Western blotting indicated that overexpression of TNS4 protein was observed in pCMV-*TNS4* vector-transfected cells ([Figure 7](#cancers-11-00601-f007){ref-type="fig"}A). Furthermore, cell migration and invasion were significantly enhanced in pCMV-*TNS4* vector-transfected cells ([Figure 7](#cancers-11-00601-f007){ref-type="fig"}B--D).

2.9. Downstream Genes Affected by the Silencing of TNS4 in LUAD Cells {#sec2dot9-cancers-11-00601}
---------------------------------------------------------------------

We performed genome-wide gene expression analysis in LUAD cells transfected with si-*TNS4* and in silico analysis to investigate the downstream genes regulated by *TNS4*. A total of 1521 downregulated genes were identified using gene expression analysis in LUAD cells transfected with si-*TNS4*. Among them, we found high expression of genes in the NSCLC clinical expression profiles from the GEO database (GEO accession no: GSE 19188). A total of 88 genes were identified as *TNS4*-modulated genes ([Table 4](#cancers-11-00601-t004){ref-type="table"} and [Figure S6](#app1-cancers-11-00601){ref-type="app"}).

3. Discussion {#sec3-cancers-11-00601}
=============

According to the current concept of miRNA biogenesis, miRNA passenger strands are degraded and have no cellular functions. In contrast to this concept, our miRNA signatures based on RNA sequencing revealed that some passenger strands are aberrantly expressed in cancer tissues \[[@B10-cancers-11-00601],[@B16-cancers-11-00601],[@B21-cancers-11-00601],[@B24-cancers-11-00601],[@B25-cancers-11-00601],[@B26-cancers-11-00601],[@B27-cancers-11-00601]\]. Importantly, functional assays showed that some passenger strands of miRNAs (e.g., *miR-144-5p*, *miR-145-3p*, *miR-139-3p*, *miR-199-3p*, *miR-223-3p,* and *miR-455-5p*) actually acted as anti-tumor miRNAs by controlling cancer-related genes \[[@B17-cancers-11-00601],[@B25-cancers-11-00601],[@B28-cancers-11-00601],[@B29-cancers-11-00601],[@B30-cancers-11-00601],[@B31-cancers-11-00601],[@B32-cancers-11-00601],[@B33-cancers-11-00601]\]. In general theory, passenger strand of miRNAs derived from miRNA-duplex have degraded in cytoplasm and have no function. In fact, the expression of passenger strand of miRNA is overwhelmingly lower than that of guide strand. Is the passenger strand of miRNA actually functional *in vivo*? This is an important issue in miRNA research. Expression levels of *miR-150-3p* were lower (100 ×) than *miR-150-5p* in LUAD cells. Our *in vitro* functional assays showed that antitumor effects are observed even if the transfection concentration of mature *miR-150-3p* is lowered (1 nM and 0.1 nM). Elucidation of functions of passenger strand of miRNA *in vivo* is an important biological theme. The involvement of passenger strands of miRNAs in cancer pathogenesis is an attractive proposal for cancer research. Identification of novel molecules controlled by miRNA (the passenger strand of miRNA duplex) will contribute to the understanding of the oncogenic networks of LUAD.

In previous studies, tumor suppressive function of *miR-150-5p* (the guide strand) was reported in several cancers \[[@B18-cancers-11-00601],[@B22-cancers-11-00601],[@B23-cancers-11-00601]\]. In contrast to this, very few reports have investigated the functional significance of *miR-150-3p* (the passenger strand) in cancer cells and its controlled cancer-related genes. We have revealed anti-tumor function of *miR-150-3p* in esophageal, head and neck, and lung squamous cell carcinomas \[[@B21-cancers-11-00601],[@B22-cancers-11-00601],[@B23-cancers-11-00601]\]. Moreover, we revealed *miR-150-3p* targets oncogenes involved in the focal adhesion pathways (e.g., *SPOCK1*, *TNC*, *ITGA3,* and *ITGA6*) \[[@B21-cancers-11-00601],[@B22-cancers-11-00601],[@B23-cancers-11-00601]\]. Importantly, these genes were overexpressed in cancer tissues and their high expression was significantly correlated with poor prognosis \[[@B21-cancers-11-00601],[@B22-cancers-11-00601],[@B23-cancers-11-00601]\].

In the present study, we finally identified four oncogenes (*TNS4*, *SFXN1*, *SKA3,* and *SPOCK1*) regulated by *miR-150-3p* in LUAD cells. Expression of these genes were significantly associated with LUAD pathogenesis. It is interesting to note that knockdown of *SPOCK1* significantly attenuated cancer cell migration and invasive abilities \[[@B21-cancers-11-00601],[@B22-cancers-11-00601],[@B23-cancers-11-00601]\]. Another target gene, *SKA3,* was overexpressed in renal cell carcinoma and its aberrant expression was associated with cancer cell malignant phenotypes \[[@B32-cancers-11-00601]\]. These data showed that target genes by *miR-150-3p* regulation closely contributed to LUAD pathogenesis and tumorigenesis. Detailed analysis of *miR-150-3p* target genes is indispensable for elucidating the molecular mechanism of LUAD.

We further investigated the oncogenic roles of *TNS4* (tensin 4) because high expression of *TNS4* was strongly associated with poor prognosis of LUAD patients (disease-free survival: *p* = 0.0213 and overall survival: *p* = 0.0003). *TNS4* (alias *CTEN*) is a member of the tensin family, which includes *TNS1*--*TNS4*. *TNS4* contains SH2 (Src homology 2) and PTB (phosphotyrosine binding) domains at the C-terminal region, both of which are shared with other tensin family members \[[@B34-cancers-11-00601]\]. Interestingly, these domains are essential to bind integrin β1, c-Cbl, β-catenin, and Eepidermal growth factor (EGF) receptor \[[@B35-cancers-11-00601],[@B36-cancers-11-00601]\]. Previous study showed that c-Cbl is an E3 ubiquitin protein ligase and induced EGFR ubiquitination. TNS4 bound to c-Cbl reduced EGFR ubiquitination and degradation \[[@B36-cancers-11-00601]\]. As a result, overexpression of TNS4 stabilized EGFR and enhanced its oncogenic signaling in cancer cells \[[@B36-cancers-11-00601]\].

Aberrant expression of *TNS4* was reported in cancers of the breast, colon, pancreas, and lung, and its expression was associated with poorer prognosis of these patients \[[@B34-cancers-11-00601],[@B37-cancers-11-00601],[@B38-cancers-11-00601],[@B39-cancers-11-00601]\]. In hepatocellular carcinoma, EGF-induced extracellular signal-regulated kinase (ERK)1/2 activation enhanced TNS4 expression and these events enhanced the epithelial--mesenchymal transition (EMT) phenotype \[[@B40-cancers-11-00601]\]. In lung cancer, TNS4 was upregulated by EGF-mediated STAT3 activation and its aberrant expression increased cancer cell invasiveness \[[@B41-cancers-11-00601]\]. Our present data confirmed the oncogenic features of *TNS4* in LUAD cells. These finding indicate that expression of *TNS4* might be a good prognostic indicator and a promising therapeutic target for LUAD.

Finally, to investigate *TNS4*-modulated oncogenes in LUAD cells, we applied genome-wide gene expression analyses using knockdown of *TNS4*. A total of 88 genes were identified as putative *TNS4*-modulated targets in LUAD cells. Aberrant expression of nine genes (*C1QTNF6*, *TNS4*, *CDK1*, *SPAG5*, *MKI67*, *CHAF1B*, *ARHGAP11A*, *PRC1*, *RHOV*, *p* \< 0.001) was closely associated with poor prognosis of patients with LUAD. Cyclin-dependent kinases (CDKs) are critical regulators of cell cycle progression and related to cancer aggressiveness. *CDK1* is essential for cycle progression during the G2/M transition and mitosis. High expression of *CDK1* is associated with poor prognosis in LUAD \[[@B42-cancers-11-00601]\]. SPAG5 is a microtubule-associated protein and is involved in regulating cell cycle progression \[[@B43-cancers-11-00601]\]. Overexpression of *SPAG5* was observed in NSCLC and promoted cell proliferation and invasion through activation of the Akt signaling pathway \[[@B44-cancers-11-00601]\]. *PRC1*, which acts as an organizing anti-parallel microtubule in the central spindle in cytokinesis, is required for tumorigenesis driven by oncogenic K-RAS and loss of p53 in a mouse model for NSCLC \[[@B45-cancers-11-00601]\]. Thus, the data revealed that many of the genes controlled by anti-tumor *miR-150-3p* and by *TNS* are closely involved in the pathogenesis of cancer. The elucidation of the novel targets controlled by anti-tumor miRNAs will accelerate comprehensive understanding of oncogenic networks of LUAD.

4. Materials and Methods {#sec4-cancers-11-00601}
========================

4.1. Human LUAD Specimens and Cell Lines {#sec4dot1-cancers-11-00601}
----------------------------------------

In this study, 18 LUAD clinical samples and 28 normal lung samples were obtained from the patients who underwent lung surgery at Kagoshima University Hospital from 2010 to 2013. [Table 1](#cancers-11-00601-t001){ref-type="table"} presents the clinical characteristics of these patients. The LUAD samples were staged according to the Association for the Study of Lung Cancer TNM classification, seventh edition.

We used the two LUAD cell lines: A549 and H1299, purchased from the American Type Culture Collection (Manassas, VA, USA).

We obtained informed consent from all of the patients. The present study was approved by the Bioethics Committee of Kagoshima University (Kagoshima, Japan; approval no. 26-164).

4.2. RNA Extraction and Quantitative Real-Time PCR {#sec4dot2-cancers-11-00601}
--------------------------------------------------

We carried out RNA extraction from formalin-fixed, paraffin-embedded specimens and cell lines and quantitative real-time reverse transcription-PCR (qRT-PCR) as previously described \[[@B18-cancers-11-00601],[@B46-cancers-11-00601],[@B47-cancers-11-00601],[@B48-cancers-11-00601]\]. The TaqMan probes and primers were listed in [Table S1](#app1-cancers-11-00601){ref-type="app"}.

4.3. Transfection of miRNAs, siRNAs, and Plasmid Vectors into LUAD Cells {#sec4dot3-cancers-11-00601}
------------------------------------------------------------------------

Transfection protocol of miRNA or siRNA species into cancer cells was described in our previous studies \[[@B18-cancers-11-00601],[@B46-cancers-11-00601],[@B47-cancers-11-00601],[@B48-cancers-11-00601]\]. The reagents used in this study are listed in [Table S1](#app1-cancers-11-00601){ref-type="app"}.

4.4. Incorporation of miR-150-5p or miR-150-3p into the RISC by Ago2 Immunoprecipitation {#sec4dot4-cancers-11-00601}
----------------------------------------------------------------------------------------

A549 cells were transfected with 10 nM miRNAs by reverse transfection. After 72 h, immunoprecipitation was performed using a microRNA Isolation Kit, Human Ago2 (Wako Pure Chemical Industries, Ltd., Osaka, Japan) as described previously \[[@B47-cancers-11-00601],[@B48-cancers-11-00601]\]. Expression levels of *miR-150-5p* and *miR-150-3p* were analyzed by qRT-PCR. MiRNA data were normalized to expressions of *miR-16-5p*, *miR-21-5p,* and *miR-26a*, which were not affected by *miR-150-5p* and *miR-150-3p*.

4.5. Cell Proliferation, Migration, and Invasion Assays {#sec4dot5-cancers-11-00601}
-------------------------------------------------------

The procedures for assessing cell proliferation, migration and invasion were described previously \[[@B18-cancers-11-00601],[@B46-cancers-11-00601],[@B47-cancers-11-00601],[@B48-cancers-11-00601]\].

4.6. Identification of Putative Target Genes Regulated by miR-150-5p and miR-150-3p in LUAD Cells {#sec4dot6-cancers-11-00601}
-------------------------------------------------------------------------------------------------

We identified putative target genes possessing sequences binding to *miR-150-5p* and *miR-150-3p* from the TargetScanHuman database (<http://www.targetscan.org/vert_72/>). GEO databases GSE19188 and GSE93290 was used for assessment of the association between target genes and the expression of NSCLC clinical specimens. Our strategy for identification of *miR-150-5p* and *miR-150-3p* target genes is outlined in [Figure S3A,B](#app1-cancers-11-00601){ref-type="app"}.

4.7. Plasmid Construction and Dual Luciferase Reporter Assay {#sec4dot7-cancers-11-00601}
------------------------------------------------------------

The following two sequences were cloned into the psiCHECK-2 vector (C8021; Promega, Madison, WI, USA): the wild-type sequence of the 3' untranslated regions (UTRs) of *TNS4*, or the deletion type, which lacked the *miR-150-3p* target sites from *TNS4*. The procedures for transfection and dual luciferase reporter assays were provided in previous studies \[[@B47-cancers-11-00601],[@B48-cancers-11-00601]\].

4.8. Clinical Database Analysis of LUAD {#sec4dot8-cancers-11-00601}
---------------------------------------

We investigated the clinical significance of miRNAs and their target genes with TCGA (<https://tcga-data.nci.nih.gov/tcga/>) in LUAD. Gene expression and clinical data were obtained from cBioPortal (<http://www.cbioportal.org/>) and OncoLnc (<http://www.oncolnc.org/>) (data downloaded on 28 September 2018) \[[@B46-cancers-11-00601],[@B47-cancers-11-00601],[@B48-cancers-11-00601],[@B49-cancers-11-00601]\].

4.9. Western Blotting and Immunohistochemistry {#sec4dot9-cancers-11-00601}
----------------------------------------------

The procedures for Western blotting and immunohistochemistry were described previously \[[@B18-cancers-11-00601],[@B46-cancers-11-00601],[@B47-cancers-11-00601],[@B48-cancers-11-00601]\]. A tissue microarray was bought from US Biomax (catalog no: BC04002a; Derwood, MD, USA). Primary antibodies were shown in [Table S1](#app1-cancers-11-00601){ref-type="app"}.

4.10. Statistical Analysis {#sec4dot10-cancers-11-00601}
--------------------------

To assess the significance of differences between two groups, we used Mann--Whitney *U* tests. Differences between multiple groups were assessed by one-way ANOVA and Tukey tests for post-hoc analysis. Tests utilized GraphPad Prism7 (GraphPad Software, La Jolla, CA, USA) and JMP Pro 14 (SAS Institute Inc., Cary, NC, USA).

5. Conclusions {#sec5-cancers-11-00601}
==============

Our results showed that the expression of both strands of the pre*-miR-150* duplex was significantly downregulated in LUAD clinical specimens and the *miR-150* duplex acted as an anti-tumor miRNA in LUAD cells. Involvement of the passenger strand of miRNA in LUAD oncogenesis suggests new possible mechanisms of pathogenesis. A total of 26 genes regulated by *miR-150-3p* were closely associated with LUAD pathogenesis. Among these targets, aberrant expression of *TNS4* enhanced cancer aggressiveness, suggesting that *TNS4* could be a promising therapeutic target for LUAD.

The following are available online at <https://www.mdpi.com/2072-6694/11/5/601/s1>. Figure S1: Functional assays of *miR-150-3p* (0.1 nM, 1 nM, 10 nM) in LUAD cells (A549 and H1299), Figure S2: Both strands of *miR-150-5p* and *miR-150-3p* were incorporated into the RISC, Figure S3: The strategy for identification of genes regulated by *miR-150-5p* and *miR-150-3p*, Figure S4: *TNS4* was directly suppressed at the diluted concentration of *miR-150-3p* precursor (1 nM and 0.1 nM), Figure S5: The nucleotide sequences of 3'UTR of *TNS4* in A549 cells, Figure S6: The strategy for identification of *TNS4*-modulated genes, Table S1: Reagent used in this study, Table S2: Immunohistochemical status and characteristics of the lung cancer and non-cancerous cases.

###### 

Click here for additional data file.
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![The clinical significance of *miR-150-5p* and *miR-150-3p* expression in lung adenocarcinoma (LUAD). (**A**,**B**) Downregulation of *miR-150-5p* and *miR-150-3p* expression in clinical specimens of LUAD and two cell lines (A549 and H1299). Expression of *RNU48* was used as an internal control. (**C**) Expression of two miRNAs derived from *miR-150*-duplex were positive correlation by Spearman's rank test. (**D**,**E**) The Kaplan--Meier overall survival curve analyses of patients with LUAD by The Cancer Genome Atlas (TCGA) database. Patients were divided into two groups according to miRNA expression and analyzed.](cancers-11-00601-g001){#cancers-11-00601-f001}

![Functional assays of *miR-150-5p* and *miR-150-3p* in LUAD cells (A549 and H1299). (**A**--**C**) Cell proliferation, migration, and invasive activities were significantly blocked by ectopic expression of *miR-150-5p* or *miR-150-3p*. \* *p* \< 0.01, \*\* *p* \< 0.05.](cancers-11-00601-g002){#cancers-11-00601-f002}

![The relationship between the expression levels of four genes (*TNS4*, *SFXN1*, *SKA3*, and *SPOCK1*) and clinical significance based on The Cancer Genome Atlas (TCGA) database. (**A**--**D**) The Kaplan--Meier disease-free survival curves and overall survival curves, T factor, N factor, M factor, and disease stage of the high- and low-expression groups for four genes (*TNS4*, *SFXN1*, *SKA3*, and *SPOCK1*).](cancers-11-00601-g003){#cancers-11-00601-f003}

![*TNS4* was directly controlled by *miR-150-3p* in LUAD cells. (**A**,**B**) *TNS4* mRNA and protein expression was reduced by *miR-150-3p* ectopic expression (48 h after transfection). *GUSB* was used as an expression control. GAPDH was used as a loading control. \* *p* \< 0.01. (**C**) Dual luciferase reporter assays using vectors encoding the wild-type *TNS4* 3′-UTR sequence containing one putative *miR-150-3p* target site (wild) and 3′-UTR sequences with deletions of the target site (deletion). Normalized data were calculated as the ratio of *Renilla*/firefly luciferase activities. \* *p* \< 0.01. UTR: untranslated region.](cancers-11-00601-g004){#cancers-11-00601-f004}

![Immunohistochemical staining of TNS4 protein in clinical LUAD specimens. (**A**,**B**) The overexpression of TNS4 was observed in the cytoplasm of cancer cells. (**C**) TNS4 was weakly stained or not detected in normal lung specimens. (**D**) Comparison of immunohistochemical staining of TNS4 in LUAD specimens and normal lung specimens. LUAD specimens showed higher expression of TNS4 than normal lung specimens.](cancers-11-00601-g005){#cancers-11-00601-f005}

![Knockdown studies of *TNS4*/TNS4 using si-*TNS4* in LUAD cells (A549 and H1299). (**A**,**B**) *TNS4* mRNA and protein expression 48 h after transfection of si-*TNS4*-1 or si-*TNS4*-2 in LUAD cell lines. (**C**--**E**) Cell proliferation, migration, and invasive activities were significantly blocked by si-*TNS4* transfection into LUAD cell lines. \* *p* \< 0.01.](cancers-11-00601-g006){#cancers-11-00601-f006}

![The effects of *TNS4* overexpression by H1299 cells. (**A**) Expression levels of TNS4 protein 48 h after transfection with pCMV-*TNS4* vector into H1299 cells. (**B**) Cell proliferation was evaluated by XTT assays. (**C**) Cell migration was determined by wound healing assay 24 h after forward transfection with the pCMV-*TNS4* vector. (**D**) Cell invasion was determined by Matrigel assay 24 h after forward transfection with the pCMV-*TNS4* vector. These assays showed that migratory and invasive activities were increased in pCMV-*TNS4* vector-transfected cell lines. \* *p* \< 0.01.](cancers-11-00601-g007){#cancers-11-00601-f007}
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###### 

Characteristics of lung cancer and non-cancerous cases.

  --------------------------------------------------- --------------- ---------
  **A. Characteristics of the Lung Cancer Cases**                     
  **Lung Cancer Patients**                            **n**           **(%)**
  Total number                                        18              
  Median age (range)                                  73.5 (59--86)   
  Gender                                                              
  Male                                                9               50.0
  Female                                              9               50.0
  Pathological stage:                                                 
  IA                                                  1               5.6
  IB                                                  4               22.2
  IIA                                                 8               44.4
  IIB                                                 1               5.6
  IIIA                                                4               22.2
  IIIB                                                0               0.0
  **B. Characteristics of the Non-Cancerous Cases**                   
  **Non-Cancerous Tissues**                           **n**           **(%)**
  Total number                                        28              
  Median age (range)                                  71 (50--88)     
  Gender:                                                             
  Male                                                25              89.3
  Female                                              3               10.7
  --------------------------------------------------- --------------- ---------

cancers-11-00601-t002_Table 2

###### 

Candidate target genes regulated by *miR-150-5p.*

  Entrez Gene   Gene Symbol   Gene Name                                                                                              Total Sites   A549 *miR-150-5p* Transfectant FC (log~2~)   GSE19188 FC (log~2~)   TCGA OncoLnc *p*-Value
  ------------- ------------- ------------------------------------------------------------------------------------------------------ ------------- -------------------------------------------- ---------------------- ------------------------
  4751          *NEK2*        NIMA-related kinase 2                                                                                  1             −0.565                                       3.323                  \<0.0001
  64065         *PERP*        PERP, TP53 apoptosis effector                                                                          3             −3.012                                       1.835                  \<0.0001
  5122          *PCSK1*       Proprotein convertase subtilisin/kexin type 1                                                          1             −0.680                                       2.532                  0.0006
  84985         *FAM83A*      Family with sequence similarity 83, member A                                                           1             −0.717                                       3.188                  0.0010
  1033          *CDKN3*       Cyclin-dependent kinase inhibitor 3                                                                    2             −0.582                                       2.889                  0.0011
  6241          *RRM2*        Ribonucleotide reductase M2                                                                            3             −2.433                                       3.000                  0.0013
  79801         *SHCBP1*      SHC SH2-domain binding protein 1                                                                       1             −1.118                                       1.841                  0.0015
  29127         *RACGAP1*     Rac GTPase activating protein 1                                                                        2             −0.545                                       1.677                  0.0019
  24137         *KIF4A*       Kinesin family member 4A                                                                               1             −0.933                                       3.309                  0.0030
  6695          *SPOCK1*      Pparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1                               1             −0.764                                       1.696                  0.0031
  9837          *GINS1*       GINS complex subunit 1 (Psf1 homolog)                                                                  2             −0.749                                       2.991                  0.0076
  339761        *CYP27C1*     Cytochrome P450, family 27, subfamily C, polypeptide 1                                                 4             −2.360                                       1.706                  0.0126
  10331         *B3GNT3*      UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3                                          2             −0.939                                       1.608                  0.0129
  79962         *DNAJC22*     DnaJ (Hsp40) homolog, subfamily C, member 22                                                           5             −0.908                                       2.031                  0.0201
  10635         *RAD51AP1*    RAD51-associated protein 1                                                                             1             −0.611                                       2.470                  0.0228
  10797         *MTHFD2*      Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase   1             −1.905                                       1.887                  0.0236
  9699          *RIMS2*       Regulating synaptic membrane exocytosis 2                                                              2             −0.697                                       1.976                  0.0265
  1058          *CENPA*       Centromere protein A                                                                                   1             −1.019                                       3.488                  0.0365
  23657         *SLC7A11*     Solute carrier family 7 (anionic amino acid transporter light chain, xc- system), member 11            3             −1.093                                       2.014                  0.0474
  3755          *KCNG1*       Potassium voltage-gated channel, subfamily G, member 1                                                 5             −1.069                                       1.887                  0.0557
  1825          *DSC3*        Desmocollin 3                                                                                          1             −1.247                                       2.488                  0.0667
  388228        *SBK1*        SH3 domain binding kinase 1                                                                            1             −0.658                                       1.745                  0.0939
  8038          *ADAM12*      ADAM metallopeptidase domain 12                                                                        2             −0.668                                       2.753                  0.1097
  84733         *CBX2*        Chromobox homolog 2                                                                                    1             −0.591                                       1.988                  0.1116
  130827        *TMEM182*     Transmembrane protein 182                                                                              1             −0.690                                       1.568                  0.1189
  92312         *MEX3A*       mex-3 RNA binding family member A                                                                      3             −0.584                                       1.986                  0.1271
  4323          *MMP14*       Matrix metallopeptidase 14                                                                             3             −0.621                                       1.872                  0.1296
  4151          *MB*          myoglobin                                                                                              3             −1.119                                       1.614                  0.1346
  57167         *SALL4*       Sal-like 4 (Drosophila)                                                                                1             −0.582                                       2.836                  0.2382
  256714        *MAP7D2*      MAP7 domain containing 2                                                                               1             −1.449                                       2.007                  0.2798
  6273          *S100A2*      S100 calcium binding protein A2                                                                        1             −0.643                                       2.513                  0.3132
  200844        *C3orf67*     Chromosome 3 open reading frame 67                                                                     1             −0.514                                       1.584                  0.3482
  1690          *COCH*        Cochlin                                                                                                2             −0.592                                       3.406                  0.3696
  10447         *FAM3C*       Family with sequence similarity 3, member C                                                            1             −1.570                                       1.536                  0.3847
  147920        *IGFL2*       IGF-like family member 2                                                                               1             −0.719                                       2.569                  0.4596
  547           *KIF1A*       Kinesin family member 1A                                                                               4             −0.733                                       2.518                  0.6354
  9066          *SYT7*        Synaptotagmin VII                                                                                      2             −0.921                                       1.730                  0.7141
  55220         *KLHDC8A*     Kelch domain containing 8A                                                                             4             −1.168                                       1.709                  0.7484
  440590        *ZYG11A*      Zyg-11 family member A, cell cycle regulator                                                           2             −1.619                                       1.826                  0.7530
  3141          *HLCS*        Holocarboxylase synthetase                                                                             1             −0.897                                       1.791                  0.8947
  9547          *CXCL14*      Chemokine (C-X-C motif) ligand 14                                                                      2             −0.750                                       1.800                  0.9229

cancers-11-00601-t003_Table 3

###### 

Candidate target genes regulated by *miR-150-3p.*

  Entrez Gene   Gene Symbol   Gene Name                                                                  Total Sites   A549 *miR-150-3p* Transfectant FC (log~2~)   GSE19188 FC (log~2~)   TCGA OncoLnc *p*-Value
  ------------- ------------- -------------------------------------------------------------------------- ------------- -------------------------------------------- ---------------------- ------------------------
  84951         *TNS4*        Tensin 4                                                                   1             −1.318                                       2.560                  0.0003
  94081         *SFXN1*       Sideroflexin 1                                                             1             −1.307                                       1.404                  0.0020
  221150        *SKA3*        Spindle and kinetochore-associated complex subunit 3                       1             −1.006                                       2.015                  0.0027
  6695          *SPOCK1*      Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1   3             −2.040                                       1.696                  0.0031
  89874         *SLC25A21*    Solute carrier family 25 (mitochondrial oxoadipate carrier), member 21     2             −2.557                                       1.358                  0.0149
  94032         *CAMK2N2*     Calcium/calmodulin-dependent protein kinase II inhibitor 2                 1             −1.303                                       1.538                  0.0208
  5738          *PTGFRN*      Prostaglandin F2 receptor inhibitor                                        2             −1.750                                       1.237                  0.0291
  23105         *FSTL4*       Follistatin-like 4                                                         1             −1.602                                       1.485                  0.0589
  130574        *LYPD6*       LY6/PLAUR domain containing 6                                              1             −1.004                                       1.917                  0.0591
  150223        *YDJC*        YdjC homolog (bacterial)                                                   1             −1.592                                       1.088                  0.0699
  3174          *HNF4G*       Hepatocyte nuclear factor 4, gamma                                         1             −1.827                                       1.709                  0.0717
  6857          *SYT1*        Synaptotagmin I                                                            1             −2.264                                       2.058                  0.0735
  5522          *PPP2R2C*     Protein phosphatase 2, regulatory subunit B, gamma                         2             −1.004                                       2.491                  0.1067
  8038          *ADAM12*      ADAM metallopeptidase domain 12                                            2             −1.555                                       2.753                  0.1097
  84216         *TMEM117*     Transmembrane protein 117                                                  1             −3.167                                       1.049                  0.1894
  55753         *OGDHL*       Oxoglutarate dehydrogenase-like                                            1             −1.896                                       1.776                  0.3167
  79944         *L2HGDH*      L-2-hydroxyglutarate dehydrogenase                                         1             −1.921                                       1.730                  0.3221
  79776         *ZFHX4*       Zinc finger homeobox 4                                                     1             −2.113                                       1.248                  0.3578
  4647          *MYO7A*       Myosin VIIA                                                                1             −1.193                                       1.047                  0.4080
  23321         *TRIM2*       Tripartite motif containing 2                                              2             −1.550                                       1.755                  0.4560
  401474        *SAMD12*      Sterile alpha motif domain containing 12                                   1             −1.950                                       1.027                  0.4853
  145282        *MIPOL1*      Mirror-image polydactyly 1                                                 1             −1.401                                       1.108                  0.5861
  8821          *INPP4B*      Inositol polyphosphate-4-phosphatase, type II, 105kDa                      3             −1.412                                       1.414                  0.6077
  80310         *PDGFD*       Platelet-derived growth factor D                                           1             −1.555                                       1.142                  0.6859
  9802          *DAZAP2*      DAZ-associated protein 2                                                   2             −1.439                                       1.144                  0.8241
  85439         *STON2*       Stonin 2                                                                   1             −1.371                                       1.079                  0.9773

cancers-11-00601-t004_Table 4

###### 

Candidate downstream genes modulated by *TNS4* in lung adenocarcinoma.

  Entrez Gene   Gene Symbol   Gene Name                                                                      GSE19188 FC (log~2~)   A549 si-*TNS4*-2 Transfectant FC (log~2~)   TCGA OncoLnc *p*-Value
  ------------- ------------- ------------------------------------------------------------------------------ ---------------------- ------------------------------------------- ------------------------
  114904        *C1QTNF6*     C1q and tumor necrosis factor related protein 6                                2.046                  −1.159                                      \<0.0001
  983           *CDK1*        Cyclin-dependent kinase 1                                                      2.400                  −1.119                                      0.0003
  10615         *SPAG5*       Sperm-associated antigen 5                                                     2.196                  −1.598                                      0.0003
  84951         *TNS4*        Tensin 4                                                                       2.560                  −2.690                                      0.0003
  4288          *MKI67*       Marker of proliferation Ki-67                                                  2.835                  −1.475                                      0.0004
  8208          *CHAF1B*      Chromatin assembly factor 1, subunit B (p60)                                   1.723                  −1.112                                      0.0005
  9824          *ARHGAP11A*   Rho GTPase activating protein 11A                                              1.638                  −1.263                                      0.0007
  9055          *PRC1*        Protein regulator of cytokinesis 1                                             2.540                  −1.120                                      0.0007
  171177        *RHOV*        Ras homolog family member V                                                    2.330                  −1.890                                      0.0008
  1033          *CDKN3*       Cyclin-dependent kinase inhibitor 3                                            2.889                  −1.594                                      0.0011
  6241          *RRM2*        Ribonucleotide reductase M2                                                    3.000                  −1.356                                      0.0013
  57405         *SPC25*       SPC25, NDC80 kinetochore complex component                                     2.417                  −1.456                                      0.0014
  5318          *PKP2*        Plakophilin 2                                                                  1.584                  −1.108                                      0.0016
  701           *BUB1B*       BUB1 mitotic checkpoint serine/threonine kinase B                              2.669                  −1.278                                      0.0017
  4085          *MAD2L1*      MAD2 mitotic arrest deficient-like 1 (yeast)                                   2.768                  −1.726                                      0.0018
  81624         *DIAPH3*      Diaphanous-related formin 3                                                    1.926                  −1.016                                      0.0022
  3832          *KIF11*       Kinesin family member 11                                                       2.479                  −1.007                                      0.0022
  79019         *CENPM*       Centromere protein M                                                           2.391                  −1.057                                      0.0023
  55635         *DEPDC1*      DEP domain containing 1                                                        3.443                  −1.282                                      0.0024
  147841        *SPC24*       SPC24, NDC80 kinetochore complex component                                     2.179                  −1.490                                      0.0031
  195828        *ZNF367*      Zinc finger protein 367                                                        1.583                  −1.454                                      0.0033
  1063          *CENPF*       Centromere protein F, 350/400kDa                                               2.985                  −1.129                                      0.0048
  83540         *NUF2*        NUF2, NDC80 kinetochore complex component                                      3.442                  −1.069                                      0.0048
  29089         *UBE2T*       Ubiquitin-conjugating enzyme E2T                                               3.317                  −1.092                                      0.0051
  7348          *UPK1B*       Uroplakin 1B                                                                   1.603                  −1.179                                      0.0059
  11130         *ZWINT*       ZW10 interacting kinetochore protein                                           2.184                  −1.188                                      0.0064
  11169         *WDHD1*       WD repeat and HMG-box DNA binding protein 1                                    2.094                  −1.151                                      0.0065
  55215         *FANCI*       Fanconi anemia, complementation group I                                        2.298                  −1.563                                      0.0073
  4176          *MCM7*        Minichromosome maintenance complex component 7                                 1.555                  −1.164                                      0.0076
  10403         *NDC80*       NDC80 kinetochore complex component                                            2.493                  −1.053                                      0.0076
  699           *BUB1*        BUB1 mitotic checkpoint serine/threonine kinase                                3.206                  −1.180                                      0.0081
  79075         *DSCC1*       DNA replication and sister chromatid cohesion 1                                1.704                  −1.187                                      0.0088
  51514         *DTL*         Denticleless E3 ubiquitin protein ligase homolog (Drosophila)                  2.098                  −1.187                                      0.0091
  8914          *TIMELESS*    Timeless circadian clock                                                       1.650                  −1.447                                      0.0093
  79733         *E2F8*        E2F transcription factor 8                                                     2.879                  −2.313                                      0.0114
  4605          *MYBL2*       v-Myb avian myeloblastosis viral oncogene homolog-like 2                       3.003                  −1.063                                      0.0122
  5427          *POLE2*       Polymerase (DNA directed), epsilon 2, accessory subunit                        1.600                  −1.074                                      0.0122
  10331         *B3GNT3*      UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3                  1.608                  −1.005                                      0.0129
  7083          *TK1*         Thymidine kinase 1, soluble                                                    2.086                  −1.399                                      0.0131
  6790          *AURKA*       Aurora kinase A                                                                2.542                  −1.018                                      0.0132
  79623         *GALNT14*     Polypeptide N-acetylgalactosaminyltransferase 14                               2.572                  −1.075                                      0.0140
  64151         *NCAPG*       Non-SMC condensin I complex, subunit G                                         2.833                  −2.675                                      0.0147
  8318          *CDC45*       Cell division cycle 45                                                         3.829                  −1.605                                      0.0159
  55165         *CEP55*       Centrosomal protein 55kDa                                                      2.875                  −1.077                                      0.0203
  54478         *FAM64A*      Family with sequence similarity 64, member A                                   2.713                  −1.697                                      0.0219
  79172         *CENPO*       Centromere protein O                                                           1.620                  −1.048                                      0.0248
  2491          *CENPI*       Centromere protein I                                                           2.088                  −1.685                                      0.0258
  1356          *CP*          Ceruloplasmin (ferroxidase)                                                    1.604                  −2.134                                      0.0300
  2244          *FGB*         Fibrinogen beta chain                                                          1.887                  −3.066                                      0.0305
  29128         *UHRF1*       Ubiquitin-like with PHD and ring finger domains 1                              2.576                  −1.442                                      0.0312
  1058          *CENPA*       Centromere protein A                                                           3.488                  −1.338                                      0.0365
  2877          *GPX2*        Glutathione peroxidase 2 (gastrointestinal)                                    3.579                  −1.038                                      0.0446
  5888          *RAD51*       RAD51 recombinase                                                              2.085                  −1.344                                      0.0478
  8438          *RAD54L*      RAD54-like (S. cerevisiae)                                                     2.920                  −1.013                                      0.0509
  1789          *DNMT3B*      DNA (cytosine-5-)-methyltransferase 3 beta                                     1.606                  −1.029                                      0.0607
  5984          *RFC4*        Replication factor C (activator 1) 4, 37kDa                                    2.004                  −1.166                                      0.0938
  91057         *CCDC34*      Coiled-coil domain containing 34                                               1.995                  −1.985                                      0.1035
  202915        *TMEM184A*    Transmembrane protein 184A                                                     1.940                  −1.983                                      0.1067
  8038          *ADAM12*      ADAM metallopeptidase domain 12                                                2.753                  −1.464                                      0.1097
  51557         *LGSN*        Lengsin, lens protein with glutamine synthetase domain                         1.721                  −1.008                                      0.1253
  4151          *MB*          Myoglobin                                                                      1.614                  −2.307                                      0.1346
  201299        *RDM1*        RAD52 motif containing 1                                                       1.503                  −1.596                                      0.1583
  5080          *PAX6*        Paired box 6                                                                   1.602                  −1.692                                      0.1649
  114907        *FBXO32*      F-box protein 32                                                               1.990                  −1.044                                      0.1654
  286151        *FBXO43*      F-box protein 43                                                               1.569                  −1.906                                      0.1729
  10293         *TRAIP*       TRAF interacting protein                                                       2.362                  −1.114                                      0.1742
  83990         *BRIP1*       BRCA1 interacting protein C-terminal helicase 1                                2.051                  −1.439                                      0.1829
  349136        *WDR86*       WD repeat domain 86                                                            1.653                  −1.306                                      0.1904
  1870          *E2F2*        E2F transcription factor 2                                                     1.704                  −1.075                                      0.1993
  3007          *HIST1H1D*    Histone cluster 1, H1d                                                         1.568                  −1.265                                      0.2918
  6676          *SPAG4*       Sperm-associated antigen 4                                                     1.552                  −1.003                                      0.3275
  200844        *C3orf67*     Chromosome 3 open reading frame 67                                             1.584                  −1.436                                      0.3482
  57016         *AKR1B10*     Aldo-keto reductase family 1, member B10 (aldose reductase)                    3.628                  −2.490                                      0.3591
  1719          *DHFR*        Dihydrofolate reductase                                                        1.538                  −1.033                                      0.4901
  8581          *LY6D*        Lymphocyte antigen 6 complex, locus D                                          2.171                  −1.384                                      0.5123
  6518          *SLC2A5*      Solute carrier family 2 (facilitated glucose/fructose transporter), member 5   1.986                  −1.018                                      0.5410
  10535         *RNASEH2A*    Ribonuclease H2, subunit A                                                     1.751                  −1.020                                      0.5517
  10018         *BCL2L11*     BCL2-like 11 (apoptosis facilitator)                                           1.592                  −1.310                                      0.5755
  25837         *RAB26*       RAB26, member RAS oncogene family                                              2.112                  −1.420                                      0.5804
  57834         *CYP4F11*     Cytochrome P450, family 4, subfamily F, polypeptide 11                         1.795                  −1.032                                      0.6899
  100133941     *CD24*        CD24 molecule                                                                  2.092                  −1.777                                      0.7765
  56521         *DNAJC12*     DnaJ (Hsp40) homolog, subfamily C, member 12                                   2.208                  −1.687                                      0.7922
  3141          *HLCS*        Holocarboxylase synthetase                                                     1.791                  −1.020                                      0.8947
  222962        *SLC29A4*     Solute carrier family 29 (equilibrative nucleoside transporter), member 4      1.617                  −1.100                                      0.9072
  1645          *AKR1C1*      Aldo-keto reductase family 1, member C1                                        2.257                  --1.546                                     0.9583
  152404        *IGSF11*      Immunoglobulin superfamily, member 11                                          1.590                  --1.572                                     0.9790
  85285         *KRTAP4-1*    Keratin-associated protein 4-1                                                 2.215                  --1.029                                     no data
  25859         *PART1*       Prostate androgen-regulated transcript 1 (non-protein coding)                  1.915                  --1.383                                     no data
